ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2022
Hospital and related resource costs associated with antimicrobial-resistant infections in Canada, 2019.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Phosphorylation by the PknB Serine/Threonine Kinase Stimulates Dimer Formation by WalR.Biochemistry · 2026Article
- Taking Charge Against the Silent Pandemic-Electrochemical Characterization of Drug Resistance.Molecules (Basel, Switzerland) · 2026Review
- Costs Associated with Failure of Vancomycin Treatment for Pneumonia and Bacteremia Due to Methicillin-ResistantThe Canadian journal of hospital pharmacy · 2026Article
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019-2023.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Designed for simplicity, used for complexity: The systemic pressures shaping walk-in clinic practices and outcomes.PloS one · 2025Article
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2018-2022.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) occurs when microorganisms become resistant to treatment by standard, or first-line, antibiotic drugs. These infections create an enormous burden on society due to longer hospital stays and increased morbidity and mortality, resulting in increased medical costs and foregone resources. The objective of this paper is to estimate the hospital costs associated with two of the most significant antibiotic-resistant organisms: methicillin-resistant Methods: The Discharge Abstract Database was employed for the analysis using a two-step process: first, the number of cases for each diagnosis was estimated; and then an average cost per case was derived, which was used to multiply the number of cases to obtain the total costs. Costs were derived using a regression model, accounting for demographic and other important confounding variables. Results: There were a total of 16,070 and 9,889 cases of Conclusion: Quantifying the outcomes associated with antimicrobial-resistant infections provides valuable information for policymakers and is an essential first step in understanding the total economic impacts of AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.